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Abstract
Introduction: Receptor activator of nuclear factor kappa B ligand (RANKL) is a key regulator of bone metabolism.
Anti-citrullinated protein antibodies (ACPA) have been suggested to cause bone destruction by osteoclast
activation. We investigated the relationship between RANKL and ACPA in patients with early untreated rheumatoid
arthritis (RA).
Methods: Patients with newly diagnosed untreated RA (n = 183) were analyzed at baseline and 3 months after
initiating methotrexate (MTX) treatment. Serum RANKL (total RANKL), ACPA (anti-CCP2) and ACPA specificities
(anti-citrullinated (cit)-vimentin, anti-cit-enolase and anti-cit-fibrinogen) were determined by enzyme-linked
immunosorbent assay (ELISA). Synovial RANKL expression was evaluated by immunohistochemistry in a small group
of patients (n = 15). The relationship between anti-cit-vim antibodies and bone destruction was further validated in
1116 RA patients included in the EIRA cohort. Pearson’s chi-square test, Wilcoxon rank sum test, Wilcoxon signed
rank test and linear regression models were used.
Results: Serum RANKL concentration was significantly higher (p <0.05) in ACPA-positive (median: 689 pmol/L, IQR
342–1253) compared with ACPA-negative (median: 159 pmol/L, IQR 96–243) patients and this difference was also
seen for synovial RANKL expression. Serum RANKL associated with ACPA (p <0.05) and bone erosions in rheumatoid
factor (RF)-negative patients (n = 59). Among ACPA specificites, anti-cit-vimentin (amino acids 60–75) was
associated with higher RANKL concentration and higher prevalence of bone erosion (p <0.05). Significant
reductions in both serum RANKL and ACPA levels were observed after 3 months of MTX treatment (p <0.05).
Conclusions: RANKL was elevated in ACPA-positive and in anti-cit-vimentin-positive patients with early untreated RA
and associated with bone erosions. These findings give further support for an early direct pathogenic link between
ACPA and bone destruction in RA.
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Introduction
Osteoimmunology is a conceptual and molecular under-
standing of how the immune system influences the bone
metabolism in diseases such as rheumatoid arthritis
(RA) [1, 2]. RA is a chronic inflammatory disease affect-
ing the synovial membrane of the joints and bone [3, 4].
Approximately half of the patients, with symptom dur-
ation of less than 1 year, present with radiographic bone
damage in small joints at diagnosis [5, 6]. Presence of
systemic autoimmunity with rheumatoid factor (RF)
and/or anti-citrullinated protein antibodies (ACPA) in
RA is associated with an increased risk of bone damage
[7–10]. Recently, a new cellular mechanism has been
suggested by which ACPA specifically increase bone
destruction in RA. According to this, ACPA binding
to the surface of osteoclast precursors increases their
number, possibly by stimulation of tumor necrosis
factor alpha (TNF-α) production [11]. In addition to
ACPA, markers of inflammation and of high disease
activity (e.g., C-reactive protein (CRP) and disease
activity score (DAS) 28) have also been shown to be
associated with increased bone damage in patients
with RA [8, 10]. Efficient treatment with disease-
modifying antirheumatic drugs (DMARD), including
methotrexate (MTX), results in reduced disease activ-
ity and less bone destruction [12], while the effect on
ACPA is still not completely elucidated [13, 14].
Receptor activator of nuclear factor kappa B ligand
(RANKL) is in the concept of osteoimmunology; a key
molecule in the regulation of bone metabolism and the
linkage between immune and skeletal systems [15, 16].
RANKL is affected by proinflammatory cytokines such as
TNF-α, interleukin (IL)-1 and IL-6 [4] and has been sug-
gested to be a marker of bone damage in RA [17–20].
However, the linkage between immune system and the
influence of ACPA immunity on RANKL in early RA is
largely unexplored. RANKL is expressed in synovial tissue
[18, 21, 22] and serum [6, 23, 24] but no studies on
RANKL’s relationship to ACPA status have been previ-
ously conducted in untreated RA.
In this study, we aimed to determine to what extent
RANKL levels associate with presence of ACPA, bone
erosions and MTX treatment in a cohort of patients
with early untreated RA.
In summary, we can report that RANKL was elevated
in ACPA-positive and in anti-cit-vimentin-positive
patients and associated with bone erosions in patients
with early untreated RA.
Methods
Patients
The study was performed in a cohort of 183 patients
with early untreated RA with symptom onset <1 year
prior to diagnosis, recruited at the Rheumatology Clinic
at Karolinska University Hospital, Stockholm (during
years 1996–2006) and part of the Epidemiological Inves-
tigation of Rheumatoid Arthritis (EIRA) study cohort
[25]. Clinical data and data on rheumatoid factor (RF)
positivity were obtained from the Swedish Rheumatology
quality registers. All patients in this study started on
MTX, with or without concomitant nonsteroidal anti-
inflammatory drugs (NSAID) and/or prednisolone, to a
final dose of 10–20 mg/week following the local guide-
lines. Regarding antiporotic treatment: 10 out of 181
patients (13 %, 2 with missing data) were on calcium
and/or vitamin D supplements and 16 out of 181 (9 %, 2
with missing data) on hormone replacement therapy,
while none was treated with either bisphosphonates or
denosumab at inclusion. An additional number of 10 out
of 181 patients (5 %) and 1 out of 181 patients (1 %)
were prescribed calcium and/or vitamin D supplement,
respectively, and/or bisphosphonates at inclusion.
Serum samples and DAS28 based on the erythrocyte
sedimentation rate (ESR) were obtained at baseline and
at clinical follow-up, which occurred after a median of
14 weeks (interquartile range 25−75 % (IQR) 13−15).
Data on the presence of HLA-DRB1 shared epitope (SE)
gene allele, protein tyrosine phosphatase gene allele
(PTPN22 rs2476601) and body mass index (BMI) at
inclusion were also available [26–28].
Review of the medical records provided information
on the presence or absence of at least one bone erosion
at baseline, based on standard radiographs of hands and
feet according to clinical routine at our unit. Seven
patients were excluded from posttreatment analyses due
to delayed MTX treatment initiation (>7 weeks after
baseline) or secession of treatment; these patients were,
however, included in pretreatment (baseline) analyses.
Additionally, 1116 patients from the EIRA study
cohort with available study data on standard radiograph
changes in hands (at least one change according to 1987
RA criteria [29]) and serum ACPA status [30], were
selected as a validation cohort. Patients in this validation
cohort had a median age of 54 years; 69 % were females,
62 % (n = 687) ACPA-positive and 36 % (n = 405) anti-
citrullinated vimentin (cit-vim)-positive. The Ethics
Review Board at Karolinska Institutet approved the study
and an informed consent was obtained from participants.
Immunoassays
ACPA were detected by anti-cyclic citrullinated peptide
version 2 (anti-CCP2) test (CCPlus Immunoscan,
Malmö, Sweden) using the manufacturer’s protocol.
ACPA levels above the highest standard sample (>3200
AU/ml) were reassessed after appropriate dilution. Anti-
bodies (anti)-cit-enolase peptide 1 (CEP-1, amino acids
5–21), anti-cit-vim peptide (amino acids 60–75), and
anti-cit-fibrinogen (fib) peptide (amino acids 563–583)
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were measured in sera by previously established
enzyme-linked immunosorbent assay (ELISA). Native
forms of the same peptides were used as controls [31].
Serum concentrations of the total (bound and unbound)
soluble RANKL were measured by ELISA (Biovendor,
Brno, Czech Republic) in accordance with the manu-
facturer’s instructions. Serum concentrations of CRP,
IL-6, and tumor necrosis factor receptor type 1
(TNF-RI) were measured by multiplex sandwich im-
munoassay (Sector Imager 6000, Meso Scale Discovery,
Gaithersburg, MD, USA) [32]. Paired samples (before and
after treatment) were run at the same assay and handled
the same way.
Synovial biopsies and immunohistochemistry
Synovial biopsies obtained during arthroscopy were
available from 15 patients with early untreated RA (in-
cluding 7 of the 183 patients that donated blood). Pa-
tients had a median age of 56 years (range 33–78); 10
out of 15 were females; 7 out of 15 were ACPA-positive
and 2 out of 15 had bone erosion at baseline. Synovial
expression of RANKL was detected by immunohisto-
chemistry staining, using a monoclonal anti-human
RANKL detection antibody at a final concentration of
5 μg/ml (12A668, Abcam, Cambridge, UK) as previ-
ously described [22, 33]. The RANKL expression level
was evaluated using computer-assisted image analysis
and expressed as the percentage of the total tissue
area that stained positive.
Statistical analysis
Pearson’s chi-square test, Wilcoxon rank sum test and
Wilcoxon signed rank test were used for independent
and paired comparisons as appropriate. To investigate
the relationship between RANKL and ACPA inde-
pendent of RF, the analysis of RANKL was performed
both in the overall group (n = 183) and also in the
subset of RF-negative patients (n = 59).
In order to investigate the association between
RANKL concentration (logarithm-transformed concen-
tration) and ACPA status, we also tested other possible
predictors for RANKL: age, sex, smoking habits (history
of ever or never smoking), BMI, DAS28-ESR, ESR, CRP,
IL-6 serum levels, TNF-RI serum levels, health assess-
ment questionnaire (HAQ) values, concurrent prednisol-
one usage, concurrent usage of antiporotic treatment,
presence of HLA-DRB1 SE, presence of PTPN22 risk
allele, one by one in univariate linear regression models.
A multiple regression model for the association between
RANKL and ACPA was then obtained by including the
significant predictors from the univariate analyses. Stat-
istical analyses were conducted using SAS 9.3 (SAS
Institute Inc., Cary, NC, USA). Two tailed p values <0.05
were considered statistically significant. No adjustments
for multiple testing were performed in the explorative
part of the study, but Bonferroni correction was applied
for comparisons in the validation cohort.
Results
Increased RANKL levels in ACPA-positive untreated early RA
Of the 183 patients, 125 (68%) were ACPA-positive with
a median concentration of 752 AU/ml (IQR 278–2174).
Among these ACPA-positive patients 58% were also
positive for anti-cit-enolase, 52% for anti-cit-vim, and
31% for anti-cit-fib (see Table 1).
Serum concentration of RANKL (Fig. 1a) was signifi-
cantly higher in ACPA-positive (689 pmol/L, IQR 342–
1253) than in ACPA-negative patients (159 pmol/L, IQR
96–243, p <0.05). Similarly, median synovial expression
of RANKL (Fig. 1b-d) was significantly higher in ACPA-
positive than in ACPA-negative patients.
To further investigate the relationship between RANKL
and ACPA independent of RF, we performed a separate
analysis of RF-negative patients. Similar to the whole
cohort, the median RANKL serum concentration
remained significantly higher in RF-negative ACPA-
positive (222 pmol/l, IRQ 194–327, n = 14) as com-
pared to RF-negative ACPA-negative patients (128
pmol/l, IRQ 88–207, n = 45, p <0.05) (Fig. 1e). Sig-
nificantly higher RANKL concentrations were also ob-
served for those who were anti-cit-enolase positive
(272 pmol/l, IQR 194–327, n = 6) or anti-cit-vim
positive (244 pmol/l, IQR 194–388, n = 7) compared
with those who were anti-cit-enolase negative (146
pmol/l, IQR 91–216, n = 53, p <0.05) or anti-cit-vim
negative (151pmol/l, IQR 90–217, n = 52, p <0.05),
respectively.
Using linear univariate regression models we identified
significant association between serum RANKL and
ACPA, age, DAS28-ESR and BMI, while all other tested
variables (sex, smoking habits, ESR, CRP, IL-6 serum
levels, TNF-RI serum levels, HAQ values, use of pred-
nisolone or antiporotic treatment, presence of HLA-
DRB1 SE and PTPN22 risk allele) were not significant
predictors for RANKL. Only ACPA and BMI remained
significant in the multivariate model. A mean of 232
pmol/l (95 % CI: 155–346) RANKL in ACPA positive
and 140 pmol/l (95 % CI: 114–171) RANKL in ACPA
negative was estimated after adjustments of age, DAS28-
ESR and BMI (Table 2).
Serum RANKL and ACPA associate with bone erosion in
untreated early RA
RANKL serum concentrations were significantly elevated
(p <0.05) in patients with evidence of bone erosions at
baseline (median 243 pmol/l, IQR 194–284, n = 9) com-
pared with those without bone erosions (151 pmol/l, IQR
91–216, n = 50) (Fig. 2a). Baseline bone erosions were
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Table 1 Characteristics at baseline of the rheumatoid arthritis cohort
ACPA-positive ACPA-negative ACPA-positive ACPA-negative
RF-negative RF-negative
Numbers 125 58 14 45
Age, years 48 (40–56) 58 (52–64) 43 (29–50) 59 (55–65)
Female sex 97 (78 %) 35 (60 %) 11 (79%) 27 (60 %)
Ever smoking 71 (66 %) 36 (67 %) 7 (64 %) 28 (67 %)
HLA-DRB1 SE 109 (89 %) 34 (60 %) 13 (100 %) 25 (57 %)
PTPN22 risk allele 40 (33 %) 10 (18 %) 5 (38 %) 6 (14 %)
DAS28-ESR 5.6 (5.0–6.2) 5.8 (5.1–6.3) 6.0 (5.2–6.2) 5.9 (5.1–6.3)
ESR 28 (16–40) 23 (12–39) 28 (25–35) 21 (12–35)
HAQ 1.1 (0.8–1.6) 1.3 (0.9–1.5) 1.0 (0.8–1.5) 1.3 (0.9–1.5)
Prednisolone 16 (13 %) 10 (18 %) 1 (7 %) 7 (16 %)
Calcium and/or vitamin D supplement 7 (6 %) 3 (5 %) 1 (7 %) 1 (2 %)
Hormone replacement therapy 9 (7 %) 7 (12 %) 0 (0 %) 5 (11 %)
RF-positive 111 (89 %) 13 (22 %)
Anti-cit-enolase (amino acids 5–21)+ 73 (58 %) 0 (0 %) 6 (43 %) 0 (0 %)
Anti-cit-vimentin (amino acids 60–75)+ 65 (52 %) 0 (0 %) 7 (50 %) 0 (0 %)
Anti-cit-fibrinogen (amino acids 563–583)+ 39 (31 %) 1 (2 %) 2 (14 %) 1 (2 %)
Values are given as number (%) or median (25–75% interquartile range: (IQR))
Number of missing observations for smoking habits, HLA-DRB1 SE, PTPN22, use of calcium and/or vitamin D, use of hormone replacement therapy, use of prednisolone
and HAQ, were 22, 3, 5, 2, 2, 5 and 4 respectively
ACPA anti-citrullinated protein antibodies, RF rheumatoid factor, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate (mmHg/hour), HAQ health






















































Fig. 1 Serum and synovial RANKL is increased in ACPA-positive as compared to ACPA-negative rheumatoid arthritis (RA). Graphs illustrate the
results of ELISA measurement of total serum RANKL concentrations in RA (a) and in RF-negative RA (e) grouped by ACPA status. Immunohistochemistry
staining shows expression of synovial RANKL in one ACPA-positive (b) and one ACPA-negative RA patient (c) and the graph illustrate the results of image
analysis in 15 patients (d). Horizontal lines represent median values, *p <0.05. ACPA anti-citrullinated protein antibodies, ELISA enzyme-linked
immunosorbent assay, RANKL receptor activator of nuclear factor kappa B ligand, RF rheumatoid factor
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Table 2 Linear regression models showed unadjusted and adjusted association between RANKL concentration and ACPA
Least square mean of RANKL pmol/L Coefficient p value R2
(95% CI) (adj R2)
ACPA- ACPA-
positive negative














R2: proportion of variance explained by the variables in the statistical model
adj R2: adjusted R2, similar to R2 but takes into account the number of variables in the model
RANKL receptor activator of nuclear factor kappa B ligand, ACPA anti-citrullinated protein antibodies, DAS28 disease activity score 28, ESR erythrocyte sedimentation rate,



















































Early RA: validation cohort
Fig. 2 Serum RANKL and ACPA associate with bone destruction. Graphs show the results of ELISA measurement of total serum RANKL
concentrations in RF-negative RA patients grouped by bone erosion status (a). ACPA-positive and anti-cit-vim-positive patients observed higher
prevalence of bone destructions than ACPA-negative or anti-cit-vim-negative patients in both early RA cohorts (b). Horizontal lines represent
median values, *p <0.05; ns: p >0.05. VC denotes validation cohort. ACPA anti-citrullinated protein antibodies, cit citrullinated, ELISA enzyme-linked
immunosorbent assay, RA rheumatoid arthritis, RANKL receptor activator of nuclear factor kappa B ligand, RF rheumatoid factor, vim vimentin
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numerically more prevalent in ACPA-positive than
ACPA-negative patients (24 vs. 16 %, p >0.05) and signifi-
cantly more prevalent in anti-cit-vim (amino acids 60–75)
-positive than anti-cit-vim-negative patients (32 vs. 15 %,
p <0.05) (Fig. 2b), while no such differences were observed
for anti-cit-enolase (amino acids 5–21) or anti-cit-fib
(amino acids 563–583) antibodies. Interestingly, this asso-
ciation appear to be independent of ACPA levels as far as
anti-cit vim (amino acids 60–75) -positive patients had a
median ACPA titer of 533 AU/ml (IQR 190–1742), while
anti-cit-fib (amino acids 563–583) -positive patients had a
significant higher median ACPA titer of 2286 AU/ml (IQR
1580–5885).
The association between anti-cit-vim (amino acids
60–75) antibodies and bone destruction finding was
confirmed in the validation cohort (n = 1116) in
which we found, that both ACPA-positive and anti-cit-vim
(amino acids 60–75) -positive patients had a higher fre-
quency of destructions in comparison to ACPA-negative
(31 vs. 22 %, Bonferroni-corrected p value <0.05) and anti-
cit-vim-negative patients (32 vs. 24 %, Bonferroni-
corrected p value <0.05), respectively (Fig. 2b).
Decreased serum RANKL levels after MTX treatment
Serum RANKL concentrations decreased significantly
following MTX treatment from baseline to 3 months
(a median decrease of 58 pmol/l, IQR 8–276, p <0.05) and
the changes were similar in the subset of RF-negative
patients. Serum RANKL levels decreased in a large
majority of the patients (83 %, Table 3). Significant
changes were observed in both RF-negative ACPA-
positive patients (a median decrease of 37 pmol/l,
IQR 5–68, p <0.05) and RF-negative ACPA-negative
patients (a median decrease of 14 pmol/l, IQR 3–38,
p <0.05). Interestingly, RANKL concentration after 3
months of MTX treatment remained higher in RF-
negative ACPA-positive patients (202 pmol/l, IQR 133–
322) than in RF-negative ACPA-negative patients (111
pmol/l, IQR 75–180, p <0.05).
Decreased serum ACPA concentrations after MTX
treatment
ACPA concentration decreased from 780 AU/ml (IRQ
273–2197) at baseline to 556 (IRQ 197–1920) at 3
months (p <0.05), for the patients that were ACPA-
positive at baseline and/or at 3 months (n = 120)
(Fig. 3a). ACPA levels decreased in a large majority of
the patients (89 %, Table 3).
Median concentrations were also observed to decrease
from baseline to 3 months for anti-cit-enolase (amino
acids 5–21) (from 23 AU/ml, IQR 11–58, to 14A U/ml,
IQR 7–38, p <0.05), anti-cit-vim (amino acids 60–75)
(from 56 AU/ml, IQR 36–130, to 37 AU/ml, IQR 25–74,
p <0.05) and anti-cit-fib (amino acids 563–583) (from
115 AU/ml, IQR 66–230, to 72 AU/ml, IQR 52–153,
p <0.05), for patients positive either at baseline or at
3 months (Fig. 3b-d). Significant decreases were also
observed when the analysis was performed on the
overall population (n = 176).
In overall population, antibody seroconversion from
positive at baseline to negative at 3 months was observed
for 3 of the 120 (2.5 %) ACPA-positive, 4 of the 71 (5.6 %)
anti-cit-enolase (amino acids 5–21) -positive, 21 of the 64
(33 %) anti-cit-vim (amino acids 60–75) -positive and 12
of the 40 (30 %) anti-cit-fib (amino acids 563–583) -posi-
tive patients. Conversion from seronegative at baseline to
seropositive at 3 months was observed infrequently: anti-
cit-vim (amino acids 60–75) (3 out of 112) (2.7 %); anti-
cit-fib (amino acids 563–583) (2 out of 136) (1.5 %). No
patients who were ACPA or anti-cit-enolase (amino acids
5–21) seronegative at baseline converted to seropositive.
Discussion
Bone destruction, essentially dependent on the effect of
RANKL on osteoclast precursors, associates with the
Table 3 Number of patients with decreased or increased levels of RANKL, IL-6, TNF-RI, ACPA and ACPA fine specificities at follow-up
Number of patients with
decreased levels




RANKL 145 (83 %) 29 (17 %) 174
IL-6 120 (68 %) 56 (32 %) 176
TNF-RI 124 (70 %) 52 (30 %) 176
ACPA 107 (89 %) 13 (11 %) 120
Anti-cit-enolase (amino acids 5–21) 58 (82 %) 13 (18 %) 71
Anti-cit-vimentin (amino acids 60–75) 59 (88 %) 8 (12 %) 67
Anti-cit-fibrinogen (amino acids 563–583) 35 (83 %) 7 (17 %) 42
Values are given as number (%). We report change in antibody concentrations for patients being positive at baseline or at 3 month for the
corresponding antibody
RANKL receptor activator of nuclear factor kappa B ligand, IL interleukin, TNF-RI tumor necrosis factor receptor type I, ACPA anti-citrullinated protein antibodies,
cit citrullinated
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presence of ACPA in RA. ACPA directly affects osteo-
clast precursors, but the relationship between ACPA and
RANKL has not yet been investigated. In this study, we
report that serum and synovial RANKL levels, used as
surrogate makers of local and systemic bone destruction,
are higher in ACPA-positive than in ACPA-negative
newly diagnosed untreated RA patients. Both ACPA and
RANKL levels decrease following treatment with metho-
trexate (MTX),.
We show that RANKL serum levels are higher in
ACPA-positive as compared to ACPA-negative patients
with early untreated RA, in contrast to one previous
study were they found difference in a degradation prod-
uct of type I collagen (CTX-I) but not RANKL [34]. De-
tection of only free RANKL (in contrast to detection of
both free and bound RANKL in our study) and/or inclu-
sion of patients with treated established RA (in contrast
to untreated early RA in our study) might explain this
discrepancy. The results presented here are in line with
a previous study showing higher levels of bone resorp-
tion markers (such as CTX-I, tartrate-resistant acid
phosphatase 5b and cathespin K) in the serum of ACPA-
positive as compared to ACPA-negative newly diagnosed
untreated RA patients [11]. Notably, the differences in
RANKL serum levels depending on ACPA status in our
study are still detectable when the analysis was
performed in the subgroup of RF-negative patients, elim-
inating the bias of RF interference. We detected rela-
tively low differences in RANKL levels between erosive
and nonerosive disease (in median a 40 % lower level in
erosive as compared to nonerosive disease) and follow-
ing therapy (in median a 20 % decrease following 3
months of treatment). However, differences of similar
magnitude have previously been shown to be of bio-
logical relevance for RA-associated bone destruction
[6]. Equally important the decrease in RANKL levels
after 3 months therapy with MYX was observed in a
majority of the patients (>80%) and is in accordance
with previous reports showing that MTX decrease
RANKL expression in both synovial tissue and
synovial-derived biopsies [22, 35, 36].
None of the measured inflammatory parameters (ESR,
CRP, IL-6 or TNF-RI, data not shown) associated with
ACPA and bone erosion in contrast to RANKL, which
suggests an association between RANKL, ACPA and bone
erosion that is at least partially uncoupled from inflam-
mation. One previous investigation of serum pre-RA sam-
ples (n = 79) failed to detect differences in RANKL serum
levels as compared to controls [37] despite more recent
reports showing signs of bone destruction in ACPA-
positive individuals already before disease onset [38]. One








































































Fig. 3 Serum concentration of ACPA and ACPA specificities. Graphs show the results of ELISA measurements of the antibody concentrations for
patients being positive at baseline or at 3 months for the corresponding antibody: ACPA n = 120 (a), anti-cit-enolase (amino acids 5–21) n = 71
(b), anti-citrullinated (cit)-vimentin (vim) (amino acids 60–75) n = 67 (c), anti-cit-fibrinogen (fib) (amino acids 563–583) antibodies n = 42 (d).
Horizontal lines represent median values, *p <0.05. Dotted lines delineate ELISA cutoff values for each antibody. ACPA anti-citrullinated protein
antibodies, ELISA enzyme-linked immunosorbent assay
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RANKL changes are only mirrored in the peripheral
blood once they reach a certain threshold at the time of
onset of clinical joint symptoms.
ACPA have previously been associated with presence
of radiological bone destruction in early RA patients
[10, 39–41] though other studies reported conflicting
results [7, 42–48]. Here, we confirmed, in one large
early RA cohort (n = 1299 in total) the association of
ACPA and presence of bone destruction. Interestingly
we were not able to detect any clear association be-
tween levels of ACPA and bone destruction. In con-
trast, presence of anti-cit-vim (amino acids 60–75)
antibodies associated with increased bone destruction
and higher levels of serum RANKL, suggesting that
these antibodies might contribute to the early bone
changes observed in ACPA-positive individuals before
disease onset [38].
Validation of our findings in other cohorts, testing for
antibodies against more cit-peptides and investigation of
the direct in vitro effect of different ACPAs specificities
on osteoclastogenesis and bone metabolism are needed.
We chose to define erosive disease as presence of at
least one erosion on X-rays of hands and feet, allowing
increased detection sensitivity in this cohort of patients
already fulfilling the 1987 ACR classification criteria, in
accordance with recently published recommendations
from a EULAR task force [49].
However, a future more detailed analysis of bone
changes (more sensitive techniques, quantification of the
changes, separate analyses of cartilage and bone mass)
not available in the current study might reveal more spe-
cific associations.
Lastly, serum RANKL, ACPA and ACPA specificities
(anti-cit-enolase (amino acids 5–21), anti-cit-vim (amino
acids 60–75), and anti-cit-fib (amino acids 563–583))
levels significantly decreased after 3 months of treatment
with MTX and a relative high proportion of patients
converted from seropositive to seronegative. These re-
sults are consistent with previous studies showing that
MTX decreased synovial expression of RANKL in vivo,
and cellular expression of RANKL in vitro [22, 35, 36].
Similar reduction in ACPA serum levels have been re-
cently reported in early RA patients treated with either
MTX in combination with sulfasalazine and hydroxy-
chloroquine or MTX in combination with infliximab
[14]. Taken together these results indicate that serocon-
version from positive to negative ACPA might occur in
patients following antirheumatic treatment. This should
be taken into consideration when characterizing treated
patients as antibody ‘seropositive’ or ‘seronegative’.
Conclusions
In summary, serum RANKL in ACPA-positive early un-
treated RA associate with erosive disease and is
modulated by MTX. Our findings give further support
for an early direct pathogenic link between ACPA and
bone destruction in RA.
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